Aeterna Zentaris Inc. announced that sales of Macrilen® (macimorelin) will be temporarily discontinued in the United States commercial market for the diagnosis of adult growth hormone deficiency (“AGHD”), effective May 23, 2023 and until anticipated re-launch with an alternate commercialization partner. This temporary action follows the August 29, 2022 announced decision by Aeterna's former North American commercialization partner Novo Nordisk Healthcare AG (“Novo Nordisk”) to end its license agreement for this product in North America. The Company is actively seeking alternate development and commercialization partners for Macrilen® (macimorelin) in the US and other territories currently not partnered.

The decision to temporarily discontinue sales of Macrilen® in the United States does not have any impact on the sales and commercialization efforts in the UK and European Economic Area. On March 16, 2023, Aeterna announced that Pharmanovia, a global lifecycle management healthcare company, had acquired the exclusive rights and license to commercialize GHRYVELIN™ (macimorelin's brand name in the UK and European Economic Area) in the territory for the diagnosis of Adult Growth Hormone Deficiency (AGHD) and, if approved, for Childhood Onset Growth Hormone Deficiency (CGHD) from the Company's previous EEA and UK partner, Consilient Health.